SlideShare a Scribd company logo
1 of 24
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
[object Object]
[object Object]
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object]
Category Type of procedure Technical Discussion Group Explanation Example 1 Formal ICH procedure EWG Development of a new guideline M5 (Data Elements and Standards for Drug Dictionaries 2 Q&A procedure IWG Creation of Q&As to assist the implementation of existing guidelines CTD-IWG 3 Revision procedure EWG Revision/Modification of existing guidelines E2B(R3) 4 Maintenance procedure EWG Adding Standards to existing guidelines and/or recommendations Q3C(R3) M2 Recommendations
[object Object],[object Object]
ICH is comprised of Six Parties that are directly involved, as well as three  Observers  and  IFPMA . The Six Parties are the founder members of ICH which represent the regulatory bodies and the research-based industry in the European Union, Japan and the USA.  These parties include the  EU ,  EFPIA ,  MHLW ,  JPMA ,  FDA  and  PhRMA The  Observers  are WHO, EFTA, and Canada (represented by Health Canada). This important group of non-voting members acts as a link between the ICH and non-ICH countries and regions.  ICH is operated via the  ICH Steering Committee , which is supported by  ICH Coordinators  and the  ICH Secretariat
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
ICH Steering Committee ICH is administered by the ICH Steering Committee which is supported by the  ICH Secretariat . The ICH Steering Committee (SC) was established in April 1990, when ICH was initiated. The Steering Committee, working with the  ICH Terms of Reference , determines the policies and procedures for ICH, selects topics for harmonisation and monitors the progress of harmonisation initiatives.  The Steering Committee meets at least twice a year with the location rotating between the three regions. Since the beginning, each of the six co-sponsors has had two seats on the ICH Steering Committee (SC) which oversees the harmonisation activities. IFPMA provides the Secretariat and participates as a non-voting member of the Steering Committee. The ICH Observers, WHO, Health Canada, and the European Free Trade Association (EFTA) nominate non-voting participants to attend the ICH Steering Committee Meetings.
OVERVIEW OF ICH GUIDELINE : 1) QUALITY: Q1A(R2) STABILITY TESTING IN NEW DRUGS AND PRODUCTS(REVISED GUIDELINE)  Q1B PHOTOSTABILITY TESTING Q1C STABILITY TESTING:NEW DOSAGE FORMS Q1D BRACKETING AND MATRIXING DESIGNS FOR STABILITY TESTING OF DRUG SUBSTANCES AND DRUG PRODUCTS Q1E EVALUATION OF STABILITY DATA Q1F STABILITY DATA PACKAGE FOR REGISTRATION IN CLIMATIC ZONES III AND IV Q2A DEFINTIONS AND TERMINOLOGY:ANALUTICAL VALIDATION Q9 QUALITY RISK MANAGEMENT Q10 PHARMACEUTICAL QUALITY SYSTEM
Q2B METHODOLOGY Q3A IMPURITY TESTING IN NEW DRUG SUBSTANCES Q3B IMPURITIES IN DOSAGE FORMS: ADDENDUN TO THE GUIDELINE ON IMPURITIES IN NEW DRUG SUBSTANCES Q3C IMPURITIES:RESIDUAL SOLVENTS Q4 PHARMACOPOEIAL HARMONIZATION Q5A VIRAL SAFETY EVALUATION Q5B GENETIC STABILITY Q5C STABILITY OF BIOTECHNOLOGY PRODUCTS Q5D CELL SUBSTRATES Q6A SPECIFICATIONS, TEST PROCEDURES, AND ACCEPTANCE CRITERIA FOR NEW DRUG SUBSTANCES AND PRODUCTS Q7A GMP FOR ACTIVE PHARMACEUTICAL INGREDIENTS Q8 PHARMACEUTICAL DEVELOPMENT
2) SAFETY : S1A GUIDELINE ON THE NEED FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS S1B TESTING FOR CARCINOGENICITY OF PHARMACEUTICALS S1C(R2) DOSE SELECTION FOR CARCINOGENICITY STUDIES  OF PHARMACEUTICALS S2(R1) GUIDANCE ON GENOTOXICITY TESTING AND DATA INTERPRETATION FOR PHARMACEUTICALS INTENDED FOR HUMAN USE S3A NOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT OF SYSTEMIC EXPOSURE IN TOXICITY STUDIES S3B PHARMACOKINETICS:GUIDANCE FOR REPEATED DOSE TISSUE DISTRIBUTION STUDIES
S4 DURATION OF CHRONIC TOXICITY TESTING IN ANIMALS (RODENT AND NON RODENT TOXICITY TESTING) S5(R2) DETECTION OF TOXICITY TO REPRODUCTION  FOR MEDICINAL PRODUCTS & TOXICITY TO MALE FERTILITY S6(R1) ADDENDUM TO ICH S6: PRECLINICAL SAFETY EVALUATION OF BIOTECHNOLOGY-DERIVED PHARMACEUTICALS S6 PRECLINICAL SAFETY EVALUATION OF  BIOTECHNOLOGY-DERIVED PHARMACEUTICALS S7A SAFETY PHARMACOLOGY STUDIES FOR HUMAN PHARMACEUTICALS S7B THE NON-CLINICAL EVALUATION OF THE POTENTIAL FOR DELAYED VENTRICULAR REPOLARIZATION (QT INTERVAL PROLONGATION) BY HUMAN PHARMACEUTICALS S8 IMMUNOTOXICITY STUDIES  FOR HUMAN PHARMACEUTICALS S9 NONCLINICAL EVALUATION FOR  ANTICANCER PHARMACEUTICALS
3) EFFICACY: E1 THE EXTENT OF POPULATION EXPOSURE TO ASSESS CLINICAL SAFETY E2A CLINICAL SAFETY DATA MANAGEMENT E2B(R2) MAINTENANCE OF THE ICH GUIDELINE ON CLINICAL SAFETY DATA MANAGEMENT  E2B(R3) REVISION OF THE ICH GUIDELINE ON CLINICAL SAFETY DATA MANAGEMENT DATA ELEMENTS FOR TRANSMISSION OF INDIVIDUAL CASE SAFETY REPORTS E2C(R1) CLINICAL SAFETY DATA MANAGEMENT: PERIODIC SAFETY UPDATE REPORTS FOR MARKETED DRUGS E2D POST-APPROVAL SAFETY DATA MANAGEMENT: DEFINITIONS AND STANDARDS FOR EXPEDITED REPORTING E2E PHARMACOVIGILANCE PLANNING E2F DEVELOPMENT SAFETY UPDATE REPORT
E3 STRUCTURE AND CONTENT OF CLINICAL STUDY REPORTS E4 DOSE-RESPONSE INFORMATION  TO SUPPORT DRUG REGISTRATION E5(R1) ETHNIC FACTORS IN THE ACCEPTABILITY OF FOREIGN CLINICAL DATA E6(R1) GUIDELINE FOR GOOD CLINICAL PRACTICE E7 STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E8 GENERAL CONSIDERATIONS FOR CLINICAL TRIALS E9 STATISTICAL PRINCIPLES FOR CLINICAL TRIALS E10 CHOICE OF CONTROL GROUP AND RELATED  ISSUES IN CLINICAL TRIALS E11 CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS IN THE PAEDIATRIC POPULATION E12 PRINCIPLES FOR CLINICAL EVALUATION OF  NEW ANTIHYPERTENSIVE DRUGS E14 THE CLINICAL EVALUATION OF QT/QTC INTERVAL PROLONGATION AND PROARRHYTHMIC POTENTIAL FOR NON-ANTIARRHYTHMIC DRUGS E15 DEFINITIONS FOR GENOMIC BIOMARKERS, PHARMACOGENOMICS, PHARMACOGENETICS, GENOMIC DATA AND SAMPLE CODING CATEGORIES E16 GENOMIC BIOMARKERS RELATED TO DRUG RESPONSE:  CONTEXT, STRUCTURE AND FORMAT OF QUALIFICATION SUBMISSIONS
4) MULTIDISCIPLINARY ; M2 (R2) ELECTRONIC TRANSMISSION OF INDIVIDUAL CASE SAFETY REPORTS MESSAGE SPECIFICATION M3(R2) GUIDANCE ON NONCLINICAL SAFETY STUDIES FOR THE CONDUCT OF  HUMAN CLINICAL TRIALS AND MARKETING AUTHORIZATION FOR PHARMACEUTICALS M4 ORGANISATION OF THE COMMON TECHNICAL DOCUMENT FOR THE REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE  M4E(R1) THE COMMON TECHNICAL DOCUMENT FOR THE REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE: EFFICACY
M4Q(R1) THE COMMON TECHNICAL DOCUMENT FOR THE REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE: QUALITY M4S(R2) THE COMMON TECHNICAL DOCUMENT FOR THE REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE: SAFETY M5 DATA ELEMENTS AND STANDARDS FOR DRUG DICTIONARIES
[object Object],Categorize ICH activities. Write a note on evaluation of stability data.
 

More Related Content

What's hot

Investigation of medicinal product dossier
Investigation of medicinal product dossierInvestigation of medicinal product dossier
Investigation of medicinal product dossierDeeptiGupta154
 
What is COPPs? How to apply for COPPs (Certificate of Pharmaceutical Products)?
What is COPPs? How to apply for COPPs (Certificate of Pharmaceutical Products)?What is COPPs? How to apply for COPPs (Certificate of Pharmaceutical Products)?
What is COPPs? How to apply for COPPs (Certificate of Pharmaceutical Products)?Ajay kamboj
 
Dossier Preparation/ CTD (Common Technical Document)
Dossier Preparation/ CTD (Common Technical Document)Dossier Preparation/ CTD (Common Technical Document)
Dossier Preparation/ CTD (Common Technical Document)Prakash Ghimire
 
Pharmaceutical Quality by Design (QbD)
Pharmaceutical Quality by Design (QbD)Pharmaceutical Quality by Design (QbD)
Pharmaceutical Quality by Design (QbD)Md. Zakaria Faruki
 
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)RaghaviPillai
 
ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA
ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA
ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA sandeep bansal
 
Marketing Authorization Procedure in European Union
Marketing Authorization Procedure in European UnionMarketing Authorization Procedure in European Union
Marketing Authorization Procedure in European UnionDoninder Hooda
 
Cmc presentation
Cmc presentationCmc presentation
Cmc presentationAsmitaGpt
 
Regulatory requirement for europe union
Regulatory requirement for europe unionRegulatory requirement for europe union
Regulatory requirement for europe unionShresthaPandey1
 
Dossier Management and Regulatory Affairs.
Dossier Management and Regulatory Affairs.Dossier Management and Regulatory Affairs.
Dossier Management and Regulatory Affairs.Naila Kanwal
 
New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)
New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)
New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)Vamsikrishna Reddy
 

What's hot (20)

Investigation of medicinal product dossier
Investigation of medicinal product dossierInvestigation of medicinal product dossier
Investigation of medicinal product dossier
 
An introduction to the EMA
An introduction to the EMAAn introduction to the EMA
An introduction to the EMA
 
What is COPPs? How to apply for COPPs (Certificate of Pharmaceutical Products)?
What is COPPs? How to apply for COPPs (Certificate of Pharmaceutical Products)?What is COPPs? How to apply for COPPs (Certificate of Pharmaceutical Products)?
What is COPPs? How to apply for COPPs (Certificate of Pharmaceutical Products)?
 
Dossier Preparation/ CTD (Common Technical Document)
Dossier Preparation/ CTD (Common Technical Document)Dossier Preparation/ CTD (Common Technical Document)
Dossier Preparation/ CTD (Common Technical Document)
 
eCTD
eCTDeCTD
eCTD
 
Pharmaceutical Quality by Design (QbD)
Pharmaceutical Quality by Design (QbD)Pharmaceutical Quality by Design (QbD)
Pharmaceutical Quality by Design (QbD)
 
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
 
ICH guidelines
ICH  guidelinesICH  guidelines
ICH guidelines
 
Anvisa
AnvisaAnvisa
Anvisa
 
eCTD Submissions
eCTD SubmissionseCTD Submissions
eCTD Submissions
 
ICH Guidelines
ICH GuidelinesICH Guidelines
ICH Guidelines
 
ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA
ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA
ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA
 
Marketing Authorization Procedure in European Union
Marketing Authorization Procedure in European UnionMarketing Authorization Procedure in European Union
Marketing Authorization Procedure in European Union
 
ACTD Guidelines Overview
ACTD Guidelines OverviewACTD Guidelines Overview
ACTD Guidelines Overview
 
INDA/NDA/ANDA
INDA/NDA/ANDAINDA/NDA/ANDA
INDA/NDA/ANDA
 
Cmc presentation
Cmc presentationCmc presentation
Cmc presentation
 
Regulatory requirement for europe union
Regulatory requirement for europe unionRegulatory requirement for europe union
Regulatory requirement for europe union
 
Dossier Management and Regulatory Affairs.
Dossier Management and Regulatory Affairs.Dossier Management and Regulatory Affairs.
Dossier Management and Regulatory Affairs.
 
Presentation on EU Regulatory & Quality System.
Presentation on EU Regulatory & Quality System.Presentation on EU Regulatory & Quality System.
Presentation on EU Regulatory & Quality System.
 
New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)
New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)
New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)
 

Viewers also liked

Design and evaluation of sustained release enteric coated tablet
Design and evaluation of sustained release enteric coated tabletDesign and evaluation of sustained release enteric coated tablet
Design and evaluation of sustained release enteric coated tabletSanjay Ananthateerta
 
pharmacopoeial standards for tablet
pharmacopoeial standards for tablet pharmacopoeial standards for tablet
pharmacopoeial standards for tablet Rohit K.
 
Sterile process validation
Sterile process validationSterile process validation
Sterile process validationSagar Savale
 
STERILE PROCESS OF VALIDATION
STERILE PROCESS OF VALIDATIONSTERILE PROCESS OF VALIDATION
STERILE PROCESS OF VALIDATIONSagar Savale
 
protein and peptide drug delivery system
protein and peptide drug delivery system protein and peptide drug delivery system
protein and peptide drug delivery system Brajesh Kumar
 
ocular drug delivery
ocular drug delivery ocular drug delivery
ocular drug delivery vsrujanav
 
Regulatory affairs-Introduction to CTD
Regulatory affairs-Introduction to CTDRegulatory affairs-Introduction to CTD
Regulatory affairs-Introduction to CTDMahesh shinde
 
Pharma regulatory affairs
Pharma regulatory affairsPharma regulatory affairs
Pharma regulatory affairsGirish Swami
 
In Process Quality Control System (IPQC) for Solid Dosages Form (Tablets)
In Process Quality Control System (IPQC) for Solid Dosages Form (Tablets)In Process Quality Control System (IPQC) for Solid Dosages Form (Tablets)
In Process Quality Control System (IPQC) for Solid Dosages Form (Tablets)Gaurav kumar
 
Drug Regulatory Affairs By Mr. Pankaj Dhapade
Drug Regulatory Affairs By Mr. Pankaj DhapadeDrug Regulatory Affairs By Mr. Pankaj Dhapade
Drug Regulatory Affairs By Mr. Pankaj DhapadePankaj Dhapade
 

Viewers also liked (20)

Ich guidelines
Ich guidelinesIch guidelines
Ich guidelines
 
Design and evaluation of sustained release enteric coated tablet
Design and evaluation of sustained release enteric coated tabletDesign and evaluation of sustained release enteric coated tablet
Design and evaluation of sustained release enteric coated tablet
 
pharmacopoeial standards for tablet
pharmacopoeial standards for tablet pharmacopoeial standards for tablet
pharmacopoeial standards for tablet
 
4 OARO - ICH Dive Inside Stability Iceberg
4 OARO - ICH Dive Inside Stability Iceberg4 OARO - ICH Dive Inside Stability Iceberg
4 OARO - ICH Dive Inside Stability Iceberg
 
Ich
Ich Ich
Ich
 
7 OARO - ICH (From Operational Site)
7 OARO - ICH (From Operational Site)7 OARO - ICH (From Operational Site)
7 OARO - ICH (From Operational Site)
 
Ctd ppt
Ctd pptCtd ppt
Ctd ppt
 
Sterile process validation
Sterile process validationSterile process validation
Sterile process validation
 
STERILE PROCESS OF VALIDATION
STERILE PROCESS OF VALIDATIONSTERILE PROCESS OF VALIDATION
STERILE PROCESS OF VALIDATION
 
Protein and peptide d d s
Protein and peptide d d sProtein and peptide d d s
Protein and peptide d d s
 
ENVIRONMENTAL MONITORING
ENVIRONMENTAL MONITORINGENVIRONMENTAL MONITORING
ENVIRONMENTAL MONITORING
 
protein and peptide drug delivery system
protein and peptide drug delivery system protein and peptide drug delivery system
protein and peptide drug delivery system
 
ocular drug delivery
ocular drug delivery ocular drug delivery
ocular drug delivery
 
Regulatory affairs-Introduction to CTD
Regulatory affairs-Introduction to CTDRegulatory affairs-Introduction to CTD
Regulatory affairs-Introduction to CTD
 
ICH GUIDELINES
ICH GUIDELINESICH GUIDELINES
ICH GUIDELINES
 
Iso 9001 2015 Understanding
Iso 9001 2015 Understanding Iso 9001 2015 Understanding
Iso 9001 2015 Understanding
 
Pharma regulatory affairs
Pharma regulatory affairsPharma regulatory affairs
Pharma regulatory affairs
 
5 OARO - ICH (Question Answers)
5 OARO - ICH (Question Answers)5 OARO - ICH (Question Answers)
5 OARO - ICH (Question Answers)
 
In Process Quality Control System (IPQC) for Solid Dosages Form (Tablets)
In Process Quality Control System (IPQC) for Solid Dosages Form (Tablets)In Process Quality Control System (IPQC) for Solid Dosages Form (Tablets)
In Process Quality Control System (IPQC) for Solid Dosages Form (Tablets)
 
Drug Regulatory Affairs By Mr. Pankaj Dhapade
Drug Regulatory Affairs By Mr. Pankaj DhapadeDrug Regulatory Affairs By Mr. Pankaj Dhapade
Drug Regulatory Affairs By Mr. Pankaj Dhapade
 

Similar to Jignesh ich

ICH GUIDELINE SPECIFIC WITH Q SERIES
ICH GUIDELINE SPECIFIC WITH Q SERIESICH GUIDELINE SPECIFIC WITH Q SERIES
ICH GUIDELINE SPECIFIC WITH Q SERIESHEALY LAD
 
ICH GUIDELINES.REGULATORY AFFAIRS...pptx
ICH GUIDELINES.REGULATORY AFFAIRS...pptxICH GUIDELINES.REGULATORY AFFAIRS...pptx
ICH GUIDELINES.REGULATORY AFFAIRS...pptxSusmitaGhosh94
 
1.5 international conference on harmonization
1.5 international conference on harmonization1.5 international conference on harmonization
1.5 international conference on harmonizationShital Patil
 
Ich guidelines seminar
Ich guidelines seminarIch guidelines seminar
Ich guidelines seminarMd Gayasuddin
 
ICH safety guidelines
ICH safety guidelinesICH safety guidelines
ICH safety guidelinesvishnu Jatoth
 
Ich quality guidelines
Ich quality guidelinesIch quality guidelines
Ich quality guidelinesSAMEERS17
 
Nivedita ICH GUIDELINES
Nivedita  ICH GUIDELINESNivedita  ICH GUIDELINES
Nivedita ICH GUIDELINESNiveditaSingla
 
Regulatory Standard - ICH-Pharmacy regulatory affairs.ppt
Regulatory Standard - ICH-Pharmacy regulatory affairs.pptRegulatory Standard - ICH-Pharmacy regulatory affairs.ppt
Regulatory Standard - ICH-Pharmacy regulatory affairs.pptArafatSaad1
 
ich-andguidemain-190106153315.pdf
ich-andguidemain-190106153315.pdfich-andguidemain-190106153315.pdf
ich-andguidemain-190106153315.pdfVaishnaviPatel76
 
ICH GUIDELINES AND ITS IMPACT IN INDIA
ICH GUIDELINES AND ITS IMPACT IN INDIAICH GUIDELINES AND ITS IMPACT IN INDIA
ICH GUIDELINES AND ITS IMPACT IN INDIAasmitadey785
 
International council for harmonisation (ich) guidelines
International council for harmonisation (ich) guidelinesInternational council for harmonisation (ich) guidelines
International council for harmonisation (ich) guidelinesMasarrat Khan
 
Toxicity studies
Toxicity studiesToxicity studies
Toxicity studiessopi_1234
 

Similar to Jignesh ich (20)

ICH
ICHICH
ICH
 
ICH GUIDELINE SPECIFIC WITH Q SERIES
ICH GUIDELINE SPECIFIC WITH Q SERIESICH GUIDELINE SPECIFIC WITH Q SERIES
ICH GUIDELINE SPECIFIC WITH Q SERIES
 
ICH GUIDELINES
ICH GUIDELINESICH GUIDELINES
ICH GUIDELINES
 
ICH GUIDELINES.REGULATORY AFFAIRS...pptx
ICH GUIDELINES.REGULATORY AFFAIRS...pptxICH GUIDELINES.REGULATORY AFFAIRS...pptx
ICH GUIDELINES.REGULATORY AFFAIRS...pptx
 
1.5 international conference on harmonization
1.5 international conference on harmonization1.5 international conference on harmonization
1.5 international conference on harmonization
 
ICH PPT
ICH PPTICH PPT
ICH PPT
 
Ich guidelines seminar
Ich guidelines seminarIch guidelines seminar
Ich guidelines seminar
 
ICH GUIDELINES.pptx
ICH GUIDELINES.pptxICH GUIDELINES.pptx
ICH GUIDELINES.pptx
 
ICH safety guidelines
ICH safety guidelinesICH safety guidelines
ICH safety guidelines
 
Ichguidelines imp
Ichguidelines impIchguidelines imp
Ichguidelines imp
 
Ich quality guidelines
Ich quality guidelinesIch quality guidelines
Ich quality guidelines
 
Nivedita ICH GUIDELINES
Nivedita  ICH GUIDELINESNivedita  ICH GUIDELINES
Nivedita ICH GUIDELINES
 
Regulatory Standard - ICH-Pharmacy regulatory affairs.ppt
Regulatory Standard - ICH-Pharmacy regulatory affairs.pptRegulatory Standard - ICH-Pharmacy regulatory affairs.ppt
Regulatory Standard - ICH-Pharmacy regulatory affairs.ppt
 
ich-andguidemain-190106153315.pdf
ich-andguidemain-190106153315.pdfich-andguidemain-190106153315.pdf
ich-andguidemain-190106153315.pdf
 
ICH AND ICH GUIDELINES
ICH AND ICH GUIDELINESICH AND ICH GUIDELINES
ICH AND ICH GUIDELINES
 
ICH GUIDELINES AND ITS IMPACT IN INDIA
ICH GUIDELINES AND ITS IMPACT IN INDIAICH GUIDELINES AND ITS IMPACT IN INDIA
ICH GUIDELINES AND ITS IMPACT IN INDIA
 
Ich guidelines ppt
Ich guidelines pptIch guidelines ppt
Ich guidelines ppt
 
ICH - quality guidelines
ICH - quality guidelinesICH - quality guidelines
ICH - quality guidelines
 
International council for harmonisation (ich) guidelines
International council for harmonisation (ich) guidelinesInternational council for harmonisation (ich) guidelines
International council for harmonisation (ich) guidelines
 
Toxicity studies
Toxicity studiesToxicity studies
Toxicity studies
 

Recently uploaded

business environment micro environment macro environment.pptx
business environment micro environment macro environment.pptxbusiness environment micro environment macro environment.pptx
business environment micro environment macro environment.pptxShruti Mittal
 
Environmental Impact Of Rotary Screw Compressors
Environmental Impact Of Rotary Screw CompressorsEnvironmental Impact Of Rotary Screw Compressors
Environmental Impact Of Rotary Screw Compressorselgieurope
 
How To Simplify Your Scheduling with AI Calendarfly The Hassle-Free Online Bo...
How To Simplify Your Scheduling with AI Calendarfly The Hassle-Free Online Bo...How To Simplify Your Scheduling with AI Calendarfly The Hassle-Free Online Bo...
How To Simplify Your Scheduling with AI Calendarfly The Hassle-Free Online Bo...SOFTTECHHUB
 
Appkodes Tinder Clone Script with Customisable Solutions.pptx
Appkodes Tinder Clone Script with Customisable Solutions.pptxAppkodes Tinder Clone Script with Customisable Solutions.pptx
Appkodes Tinder Clone Script with Customisable Solutions.pptxappkodes
 
20220816-EthicsGrade_Scorecard-JP_Morgan_Chase-Q2-63_57.pdf
20220816-EthicsGrade_Scorecard-JP_Morgan_Chase-Q2-63_57.pdf20220816-EthicsGrade_Scorecard-JP_Morgan_Chase-Q2-63_57.pdf
20220816-EthicsGrade_Scorecard-JP_Morgan_Chase-Q2-63_57.pdfChris Skinner
 
PSCC - Capability Statement Presentation
PSCC - Capability Statement PresentationPSCC - Capability Statement Presentation
PSCC - Capability Statement PresentationAnamaria Contreras
 
Driving Business Impact for PMs with Jon Harmer
Driving Business Impact for PMs with Jon HarmerDriving Business Impact for PMs with Jon Harmer
Driving Business Impact for PMs with Jon HarmerAggregage
 
Onemonitar Android Spy App Features: Explore Advanced Monitoring Capabilities
Onemonitar Android Spy App Features: Explore Advanced Monitoring CapabilitiesOnemonitar Android Spy App Features: Explore Advanced Monitoring Capabilities
Onemonitar Android Spy App Features: Explore Advanced Monitoring CapabilitiesOne Monitar
 
Types of Cyberattacks - ASG I.T. Consulting.pdf
Types of Cyberattacks - ASG I.T. Consulting.pdfTypes of Cyberattacks - ASG I.T. Consulting.pdf
Types of Cyberattacks - ASG I.T. Consulting.pdfASGITConsulting
 
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptx
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptxThe-Ethical-issues-ghhhhhhhhjof-Byjus.pptx
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptxmbikashkanyari
 
Excvation Safety for safety officers reference
Excvation Safety for safety officers referenceExcvation Safety for safety officers reference
Excvation Safety for safety officers referencessuser2c065e
 
1911 Gold Corporate Presentation Apr 2024.pdf
1911 Gold Corporate Presentation Apr 2024.pdf1911 Gold Corporate Presentation Apr 2024.pdf
1911 Gold Corporate Presentation Apr 2024.pdfShaun Heinrichs
 
Jewish Resources in the Family Resource Centre
Jewish Resources in the Family Resource CentreJewish Resources in the Family Resource Centre
Jewish Resources in the Family Resource CentreNZSG
 
Interoperability and ecosystems: Assembling the industrial metaverse
Interoperability and ecosystems:  Assembling the industrial metaverseInteroperability and ecosystems:  Assembling the industrial metaverse
Interoperability and ecosystems: Assembling the industrial metaverseSiemens
 
Welding Electrode Making Machine By Deccan Dynamics
Welding Electrode Making Machine By Deccan DynamicsWelding Electrode Making Machine By Deccan Dynamics
Welding Electrode Making Machine By Deccan DynamicsIndiaMART InterMESH Limited
 
Pitch Deck Teardown: Xpanceo's $40M Seed deck
Pitch Deck Teardown: Xpanceo's $40M Seed deckPitch Deck Teardown: Xpanceo's $40M Seed deck
Pitch Deck Teardown: Xpanceo's $40M Seed deckHajeJanKamps
 
Psychic Reading | Spiritual Guidance – Astro Ganesh Ji
Psychic Reading | Spiritual Guidance – Astro Ganesh JiPsychic Reading | Spiritual Guidance – Astro Ganesh Ji
Psychic Reading | Spiritual Guidance – Astro Ganesh Jiastral oracle
 
Memorándum de Entendimiento (MoU) entre Codelco y SQM
Memorándum de Entendimiento (MoU) entre Codelco y SQMMemorándum de Entendimiento (MoU) entre Codelco y SQM
Memorándum de Entendimiento (MoU) entre Codelco y SQMVoces Mineras
 
20200128 Ethical by Design - Whitepaper.pdf
20200128 Ethical by Design - Whitepaper.pdf20200128 Ethical by Design - Whitepaper.pdf
20200128 Ethical by Design - Whitepaper.pdfChris Skinner
 

Recently uploaded (20)

business environment micro environment macro environment.pptx
business environment micro environment macro environment.pptxbusiness environment micro environment macro environment.pptx
business environment micro environment macro environment.pptx
 
Environmental Impact Of Rotary Screw Compressors
Environmental Impact Of Rotary Screw CompressorsEnvironmental Impact Of Rotary Screw Compressors
Environmental Impact Of Rotary Screw Compressors
 
How To Simplify Your Scheduling with AI Calendarfly The Hassle-Free Online Bo...
How To Simplify Your Scheduling with AI Calendarfly The Hassle-Free Online Bo...How To Simplify Your Scheduling with AI Calendarfly The Hassle-Free Online Bo...
How To Simplify Your Scheduling with AI Calendarfly The Hassle-Free Online Bo...
 
Appkodes Tinder Clone Script with Customisable Solutions.pptx
Appkodes Tinder Clone Script with Customisable Solutions.pptxAppkodes Tinder Clone Script with Customisable Solutions.pptx
Appkodes Tinder Clone Script with Customisable Solutions.pptx
 
20220816-EthicsGrade_Scorecard-JP_Morgan_Chase-Q2-63_57.pdf
20220816-EthicsGrade_Scorecard-JP_Morgan_Chase-Q2-63_57.pdf20220816-EthicsGrade_Scorecard-JP_Morgan_Chase-Q2-63_57.pdf
20220816-EthicsGrade_Scorecard-JP_Morgan_Chase-Q2-63_57.pdf
 
PSCC - Capability Statement Presentation
PSCC - Capability Statement PresentationPSCC - Capability Statement Presentation
PSCC - Capability Statement Presentation
 
Driving Business Impact for PMs with Jon Harmer
Driving Business Impact for PMs with Jon HarmerDriving Business Impact for PMs with Jon Harmer
Driving Business Impact for PMs with Jon Harmer
 
Onemonitar Android Spy App Features: Explore Advanced Monitoring Capabilities
Onemonitar Android Spy App Features: Explore Advanced Monitoring CapabilitiesOnemonitar Android Spy App Features: Explore Advanced Monitoring Capabilities
Onemonitar Android Spy App Features: Explore Advanced Monitoring Capabilities
 
Types of Cyberattacks - ASG I.T. Consulting.pdf
Types of Cyberattacks - ASG I.T. Consulting.pdfTypes of Cyberattacks - ASG I.T. Consulting.pdf
Types of Cyberattacks - ASG I.T. Consulting.pdf
 
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptx
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptxThe-Ethical-issues-ghhhhhhhhjof-Byjus.pptx
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptx
 
Excvation Safety for safety officers reference
Excvation Safety for safety officers referenceExcvation Safety for safety officers reference
Excvation Safety for safety officers reference
 
WAM Corporate Presentation April 12 2024.pdf
WAM Corporate Presentation April 12 2024.pdfWAM Corporate Presentation April 12 2024.pdf
WAM Corporate Presentation April 12 2024.pdf
 
1911 Gold Corporate Presentation Apr 2024.pdf
1911 Gold Corporate Presentation Apr 2024.pdf1911 Gold Corporate Presentation Apr 2024.pdf
1911 Gold Corporate Presentation Apr 2024.pdf
 
Jewish Resources in the Family Resource Centre
Jewish Resources in the Family Resource CentreJewish Resources in the Family Resource Centre
Jewish Resources in the Family Resource Centre
 
Interoperability and ecosystems: Assembling the industrial metaverse
Interoperability and ecosystems:  Assembling the industrial metaverseInteroperability and ecosystems:  Assembling the industrial metaverse
Interoperability and ecosystems: Assembling the industrial metaverse
 
Welding Electrode Making Machine By Deccan Dynamics
Welding Electrode Making Machine By Deccan DynamicsWelding Electrode Making Machine By Deccan Dynamics
Welding Electrode Making Machine By Deccan Dynamics
 
Pitch Deck Teardown: Xpanceo's $40M Seed deck
Pitch Deck Teardown: Xpanceo's $40M Seed deckPitch Deck Teardown: Xpanceo's $40M Seed deck
Pitch Deck Teardown: Xpanceo's $40M Seed deck
 
Psychic Reading | Spiritual Guidance – Astro Ganesh Ji
Psychic Reading | Spiritual Guidance – Astro Ganesh JiPsychic Reading | Spiritual Guidance – Astro Ganesh Ji
Psychic Reading | Spiritual Guidance – Astro Ganesh Ji
 
Memorándum de Entendimiento (MoU) entre Codelco y SQM
Memorándum de Entendimiento (MoU) entre Codelco y SQMMemorándum de Entendimiento (MoU) entre Codelco y SQM
Memorándum de Entendimiento (MoU) entre Codelco y SQM
 
20200128 Ethical by Design - Whitepaper.pdf
20200128 Ethical by Design - Whitepaper.pdf20200128 Ethical by Design - Whitepaper.pdf
20200128 Ethical by Design - Whitepaper.pdf
 

Jignesh ich

  • 1.
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.
  • 10. Category Type of procedure Technical Discussion Group Explanation Example 1 Formal ICH procedure EWG Development of a new guideline M5 (Data Elements and Standards for Drug Dictionaries 2 Q&A procedure IWG Creation of Q&As to assist the implementation of existing guidelines CTD-IWG 3 Revision procedure EWG Revision/Modification of existing guidelines E2B(R3) 4 Maintenance procedure EWG Adding Standards to existing guidelines and/or recommendations Q3C(R3) M2 Recommendations
  • 11.
  • 12. ICH is comprised of Six Parties that are directly involved, as well as three Observers and IFPMA . The Six Parties are the founder members of ICH which represent the regulatory bodies and the research-based industry in the European Union, Japan and the USA. These parties include the EU , EFPIA , MHLW , JPMA , FDA and PhRMA The Observers are WHO, EFTA, and Canada (represented by Health Canada). This important group of non-voting members acts as a link between the ICH and non-ICH countries and regions. ICH is operated via the ICH Steering Committee , which is supported by ICH Coordinators and the ICH Secretariat
  • 13.
  • 14. ICH Steering Committee ICH is administered by the ICH Steering Committee which is supported by the ICH Secretariat . The ICH Steering Committee (SC) was established in April 1990, when ICH was initiated. The Steering Committee, working with the ICH Terms of Reference , determines the policies and procedures for ICH, selects topics for harmonisation and monitors the progress of harmonisation initiatives. The Steering Committee meets at least twice a year with the location rotating between the three regions. Since the beginning, each of the six co-sponsors has had two seats on the ICH Steering Committee (SC) which oversees the harmonisation activities. IFPMA provides the Secretariat and participates as a non-voting member of the Steering Committee. The ICH Observers, WHO, Health Canada, and the European Free Trade Association (EFTA) nominate non-voting participants to attend the ICH Steering Committee Meetings.
  • 15. OVERVIEW OF ICH GUIDELINE : 1) QUALITY: Q1A(R2) STABILITY TESTING IN NEW DRUGS AND PRODUCTS(REVISED GUIDELINE) Q1B PHOTOSTABILITY TESTING Q1C STABILITY TESTING:NEW DOSAGE FORMS Q1D BRACKETING AND MATRIXING DESIGNS FOR STABILITY TESTING OF DRUG SUBSTANCES AND DRUG PRODUCTS Q1E EVALUATION OF STABILITY DATA Q1F STABILITY DATA PACKAGE FOR REGISTRATION IN CLIMATIC ZONES III AND IV Q2A DEFINTIONS AND TERMINOLOGY:ANALUTICAL VALIDATION Q9 QUALITY RISK MANAGEMENT Q10 PHARMACEUTICAL QUALITY SYSTEM
  • 16. Q2B METHODOLOGY Q3A IMPURITY TESTING IN NEW DRUG SUBSTANCES Q3B IMPURITIES IN DOSAGE FORMS: ADDENDUN TO THE GUIDELINE ON IMPURITIES IN NEW DRUG SUBSTANCES Q3C IMPURITIES:RESIDUAL SOLVENTS Q4 PHARMACOPOEIAL HARMONIZATION Q5A VIRAL SAFETY EVALUATION Q5B GENETIC STABILITY Q5C STABILITY OF BIOTECHNOLOGY PRODUCTS Q5D CELL SUBSTRATES Q6A SPECIFICATIONS, TEST PROCEDURES, AND ACCEPTANCE CRITERIA FOR NEW DRUG SUBSTANCES AND PRODUCTS Q7A GMP FOR ACTIVE PHARMACEUTICAL INGREDIENTS Q8 PHARMACEUTICAL DEVELOPMENT
  • 17. 2) SAFETY : S1A GUIDELINE ON THE NEED FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS S1B TESTING FOR CARCINOGENICITY OF PHARMACEUTICALS S1C(R2) DOSE SELECTION FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS S2(R1) GUIDANCE ON GENOTOXICITY TESTING AND DATA INTERPRETATION FOR PHARMACEUTICALS INTENDED FOR HUMAN USE S3A NOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT OF SYSTEMIC EXPOSURE IN TOXICITY STUDIES S3B PHARMACOKINETICS:GUIDANCE FOR REPEATED DOSE TISSUE DISTRIBUTION STUDIES
  • 18. S4 DURATION OF CHRONIC TOXICITY TESTING IN ANIMALS (RODENT AND NON RODENT TOXICITY TESTING) S5(R2) DETECTION OF TOXICITY TO REPRODUCTION FOR MEDICINAL PRODUCTS & TOXICITY TO MALE FERTILITY S6(R1) ADDENDUM TO ICH S6: PRECLINICAL SAFETY EVALUATION OF BIOTECHNOLOGY-DERIVED PHARMACEUTICALS S6 PRECLINICAL SAFETY EVALUATION OF BIOTECHNOLOGY-DERIVED PHARMACEUTICALS S7A SAFETY PHARMACOLOGY STUDIES FOR HUMAN PHARMACEUTICALS S7B THE NON-CLINICAL EVALUATION OF THE POTENTIAL FOR DELAYED VENTRICULAR REPOLARIZATION (QT INTERVAL PROLONGATION) BY HUMAN PHARMACEUTICALS S8 IMMUNOTOXICITY STUDIES FOR HUMAN PHARMACEUTICALS S9 NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS
  • 19. 3) EFFICACY: E1 THE EXTENT OF POPULATION EXPOSURE TO ASSESS CLINICAL SAFETY E2A CLINICAL SAFETY DATA MANAGEMENT E2B(R2) MAINTENANCE OF THE ICH GUIDELINE ON CLINICAL SAFETY DATA MANAGEMENT E2B(R3) REVISION OF THE ICH GUIDELINE ON CLINICAL SAFETY DATA MANAGEMENT DATA ELEMENTS FOR TRANSMISSION OF INDIVIDUAL CASE SAFETY REPORTS E2C(R1) CLINICAL SAFETY DATA MANAGEMENT: PERIODIC SAFETY UPDATE REPORTS FOR MARKETED DRUGS E2D POST-APPROVAL SAFETY DATA MANAGEMENT: DEFINITIONS AND STANDARDS FOR EXPEDITED REPORTING E2E PHARMACOVIGILANCE PLANNING E2F DEVELOPMENT SAFETY UPDATE REPORT
  • 20. E3 STRUCTURE AND CONTENT OF CLINICAL STUDY REPORTS E4 DOSE-RESPONSE INFORMATION TO SUPPORT DRUG REGISTRATION E5(R1) ETHNIC FACTORS IN THE ACCEPTABILITY OF FOREIGN CLINICAL DATA E6(R1) GUIDELINE FOR GOOD CLINICAL PRACTICE E7 STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E8 GENERAL CONSIDERATIONS FOR CLINICAL TRIALS E9 STATISTICAL PRINCIPLES FOR CLINICAL TRIALS E10 CHOICE OF CONTROL GROUP AND RELATED ISSUES IN CLINICAL TRIALS E11 CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS IN THE PAEDIATRIC POPULATION E12 PRINCIPLES FOR CLINICAL EVALUATION OF NEW ANTIHYPERTENSIVE DRUGS E14 THE CLINICAL EVALUATION OF QT/QTC INTERVAL PROLONGATION AND PROARRHYTHMIC POTENTIAL FOR NON-ANTIARRHYTHMIC DRUGS E15 DEFINITIONS FOR GENOMIC BIOMARKERS, PHARMACOGENOMICS, PHARMACOGENETICS, GENOMIC DATA AND SAMPLE CODING CATEGORIES E16 GENOMIC BIOMARKERS RELATED TO DRUG RESPONSE: CONTEXT, STRUCTURE AND FORMAT OF QUALIFICATION SUBMISSIONS
  • 21. 4) MULTIDISCIPLINARY ; M2 (R2) ELECTRONIC TRANSMISSION OF INDIVIDUAL CASE SAFETY REPORTS MESSAGE SPECIFICATION M3(R2) GUIDANCE ON NONCLINICAL SAFETY STUDIES FOR THE CONDUCT OF HUMAN CLINICAL TRIALS AND MARKETING AUTHORIZATION FOR PHARMACEUTICALS M4 ORGANISATION OF THE COMMON TECHNICAL DOCUMENT FOR THE REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE M4E(R1) THE COMMON TECHNICAL DOCUMENT FOR THE REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE: EFFICACY
  • 22. M4Q(R1) THE COMMON TECHNICAL DOCUMENT FOR THE REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE: QUALITY M4S(R2) THE COMMON TECHNICAL DOCUMENT FOR THE REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE: SAFETY M5 DATA ELEMENTS AND STANDARDS FOR DRUG DICTIONARIES
  • 23.
  • 24.